Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaccine composition for transdermal or mucosal administration

A technology of vaccine composition and mucosal administration, applied in drug combination, microorganism, drug delivery, etc., can solve the problems of heat-labile enterotoxin, administration to difficult-to-skilled medical workers, needle stick infection accident patients, etc., and achieve high cellular immunity induction effect, the effect of enhancing the effect of inducing cellular immunity

Inactive Publication Date: 2014-08-06
NITTO DENKO CORP
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, injections have the following problems: pain, fear, injection scars and scars developed from injection scars, only medical workers can perform injections, intradermal injections with high immune effects are difficult to administer, and there are needles for medical workers. It cannot be said to be the best route of administration because of the risk of infection accidents, the need to go to the hospital frequently when repeated administration is a burden on the patient's life, and the generation of medical waste that requires special disposal such as injection needles.
As an adjuvant studied in immunization by means other than injection, for example, by transdermal administration or transmucosal administration, aluminum salts such as aluminum hydroxide, aluminum phosphate, and aluminum chloride are listed; cholera toxin, Escherichia coli Toxins such as heat-resistant enterotoxin, etc., but not yet in use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine composition for transdermal or mucosal administration
  • Vaccine composition for transdermal or mucosal administration
  • Vaccine composition for transdermal or mucosal administration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0406] Strip preparation for transdermal administration

[0407] The adhesive used in the tape preparation was prepared as shown below.

[0408] (Acrylic Adhesive A)

[0409] In an inert gas atmosphere, 75 parts of 2-ethylhexyl acrylate, 22 parts of N-vinyl-2-pyrrolidone, 3 parts of acrylic acid and 0.2 parts of azobisisobutyronitrile were carried out in ethyl acetate at 60 ° C. Solution polymerization was carried out to obtain an acrylic adhesive A solution.

[0410] (PIB rubber-based adhesive)

[0411] 24 parts of polyisobutylene (Opanol B200, manufactured by BASF Corporation), 36 parts of polyisobutylene (Opanol B12, manufactured by BASF Corporation), and 40 parts of alicyclic petroleum resin (ALCON P-100, manufactured by Arakawa Chemical Co., Ltd.) were dissolved in toluene , to obtain a PIB rubber-based adhesive solution.

[0412] Strip preparations having the compositions of the following Tables 1 to 3 were produced. Specifically, an adhesive solution, an antigeni...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
Login to View More

Abstract

The invention relates to a vaccine composition for transdermal or mucosal administration, and provides a vaccine composition including a cellular immunity promoter that is used commonly with respect to various antigens in cellular immunity induction by transdermal or transmucosal administration of an antigen, having high convenience, and providing high cellular immunity inducing effect in transdermal or transmucosal administration. The vaccine composition for transdermal or transmucosal administration for inducing cellular immunity, comprising (i) an antigen; and (ii) a pharmacologically acceptable acid or a pharmacologically acceptable salt thereof as a first cellular immunity induction promoter.

Description

technical field [0001] The present invention relates to vaccine compositions for transdermal or transmucosal administration. Background technique [0002] Vaccines that are widely used generally administer pathogens such as microorganisms or viruses or parts thereof in order to induce immunity. In addition, there are cancer vaccines, the purpose of which is to enable the cellular immune system to recognize cancer cell-specific antigens, thereby inducing a specific attack on cancer cells through the immune system, which is used as one of the means of cancer treatment. [0003] Usually, the invasion of microorganisms, viruses, due to their size, is prevented by the skin, therefore, vaccines need to be administered invasively into the body. Thus, immunization usually uses injections. However, injections have the following problems: pain, fear, injection scars and scars developed from injection scars, only medical workers can perform injections, intradermal injections with hig...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/00A61K9/00A61K47/12A61P37/04A61P35/00
CPCA61K39/0011A61K39/12A61K2039/54A61K2039/541A61K2039/55511A61K2039/55516A61K2039/55572C12N2770/24234A61K31/4745A61K31/739A61P31/12A61P35/00A61P37/04A61K39/00117A61K39/00115A61K39/001106A61K39/001186A61K9/0014A61K9/006A61K38/10
Inventor 前田佳己大久保胜之浅利大介冈崎有道宍户卓矢松下恭平李文婧堀光彦杉山治夫
Owner NITTO DENKO CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com